IVA (Inventiva) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IVA Inventiva SA IVA
37 GF Score
Price $4.30
GF Value $0.28
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Inventiva SpecialCharges?

Special Charges only applies to banks.

IVA
37GF Score
Inventiva SA IVA
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Inventiva (IVA) Overvalued in 2026?

Based on GuruFocus' analysis, Inventiva stock appears to be overvalued. The current stock price of $4.30 is trading 1433.9% above its estimated GF Value™ of $0.28. GuruFocus considers Inventiva to be Significantly Overvalued.

Key valuation signals for IVA:

  • SpecialCharges:
  • GF Value™: $0.28 vs. price of $4.30 (1433.9% above fair value)
  • GF Score™: 37/100 with 7 warning signs

No single metric tells the full story. See the IVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inventiva Business Description

Address 50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
37GF Score

Get the complete analysis for IVA

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.30
Price
$0.28
GF Value